Churchill Capital Corp XI (CCXI)vsNew Providence Acquisition Corp. III Class A Ordinary Shares (NPAC)
CCXI
Churchill Capital Corp XI
$12.90
+6.83%
FINANCIAL SERVICES · Cap: $746.38M
NPAC
New Providence Acquisition Corp. III Class A Ordinary Shares
$10.47
0.00%
FINANCIAL SERVICES · Cap: $402.31M
Smart Verdict
WallStSmart Research — data-driven comparison
NPAC leads profitability with a 0.0% profit margin vs 0.0%. NPAC earns a higher WallStSmart Score of 30/100 (F).
CCXI
Avoid23
out of 100
Grade: F
NPAC
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% revenue growth
Smaller company, higher risk/reward
ROE of 3.0% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : CCXI
CCXI has a balanced fundamental profile.
Bull Case : NPAC
NPAC has a balanced fundamental profile.
Bear Case : CCXI
The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NPAC
The primary concerns for NPAC are Revenue Growth, Market Cap, Return on Equity. A P/E of 41.9x leaves little room for execution misses.
Key Dynamics to Monitor
NPAC is growing revenue faster at 0.0% — sustainability is the question.
CCXI generates stronger free cash flow (-157,581), providing more financial flexibility.
Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NPAC scores higher overall (30/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Churchill Capital Corp XI
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
New Providence Acquisition Corp. III Class A Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
New Providence Acquisition Corp. III (NPAC) is a special purpose acquisition company (SPAC) focused on merging with innovative growth enterprises, primarily in the technology sector. The company aims to partner with exceptional management teams to unlock significant long-term value for its investors. With robust financial resources and strategic insights, NPAC is well-positioned to seize emerging market opportunities and deliver attractive returns in a rapidly evolving economic landscape.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?